This clinical trial is focused on studying the treatment of Atopic Dermatitis, a condition commonly known as eczema, which causes the skin to become itchy, red, and inflamed. The study involves two treatments: Upadacitinib, which is taken as an oral solution or a modified-release tablet, and Dupilumab, which is given as a solution for injection. The purpose of the study is to compare the safety and effectiveness of these two treatments in children aged 2 to less than 12 years who have moderate to severe atopic dermatitis.
Participants in the study will receive either Upadacitinib or Dupilumab. The study will last for several weeks, during which the children will be monitored to see how their skin condition improves and to check for any side effects. The study aims to find out which treatment works better in reducing the symptoms of atopic dermatitis, such as the extent and severity of the eczema, and to ensure that the treatments are safe for use in children.
Throughout the study, the children will have regular check-ups to assess their progress. The main goal is to see if there is a significant reduction in the eczema symptoms by the end of the study period. This research is important for understanding how these treatments can help manage atopic dermatitis in young children and improve their quality of life.
Austria 
Bulgaria 
Croatia 
France 
Germany 
Hungary 
Italy 
Poland 
Portugal 
Slovakia 
Spain 
The Netherlands 
